{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:30:56Z","timestamp":1793129456901,"version":"4.5.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,8]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor T-cell (CAR T) therapy has produced remarkable clinical responses in B-cell neoplasms. However, many challenges limit this class of agents for the treatment of other cancer types, in particular the lack of tumor-selective antigens for solid tumors and other hematological malignancies, such as acute myeloid leukemia (AML), which may be addressed without significant risk of severe toxicities while providing sufficient abundance for efficient tumor suppression. One approach to overcome this hurdle is dual targeting by an antibody\u2013T-cell receptor (AbTCR) and a chimeric costimulatory signaling receptor (CSR) to 2 different antigens, in which both antigens are found together on the cancer cells but not together on normal cells. To explore this proof of concept in AML, we engineered a new T-cell format targeting Wilms tumor 1 protein (WT1) and CD33; both are highly expressed on most AML cells. Using an AbTCR comprising a newly developed TCR-mimic monoclonal antibody against the WT1 RMFPNAPYL (RMF) epitope\/HLA-A2 complex, ESK2, and a secondary CSR comprising a single-chain variable fragment directed to CD33 linked to a truncated CD28 costimulatory fragment, this unique platform confers specific T-cell cytotoxicity to the AML cells while sparing healthy hematopoietic cells, including CD33+ myelomonocytic normal cells. These data suggest that this new platform, named AbTCR-CSR, through the combination of a AbTCR CAR and CSR could be an effective strategy to reduce toxicity and improve specificity and clinical outcomes in adoptive T-cell therapy in AML.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023021054","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T22:01:55Z","timestamp":1701727315000},"page":"507-521","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":29,"title":["A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9937-6283","authenticated-orcid":false,"given":"Tao","family":"Dao","sequence":"first","affiliation":[{"name":"1Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyan","family":"Xiong","sequence":"additional","affiliation":[{"name":"2Eureka Therapeutics Inc, Emeryville, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Soo","family":"Mun","sequence":"additional","affiliation":[{"name":"1Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7029-847X","authenticated-orcid":false,"given":"Jeremy","family":"Meyerberg","sequence":"additional","affiliation":[{"name":"1Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Korontsvit","sequence":"additional","affiliation":[{"name":"1Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2147-7905","authenticated-orcid":false,"given":"Jingyi","family":"Xiang","sequence":"additional","affiliation":[{"name":"2Eureka Therapeutics Inc, Emeryville, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4002-2509","authenticated-orcid":false,"given":"Ziyou","family":"Cui","sequence":"additional","affiliation":[{"name":"2Eureka Therapeutics Inc, Emeryville, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7770-7405","authenticated-orcid":false,"given":"Aaron Y.","family":"Chang","sequence":"additional","affiliation":[{"name":"1Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9598-6615","authenticated-orcid":false,"given":"Casey","family":"Jarvis","sequence":"additional","affiliation":[{"name":"1Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7121-0986","authenticated-orcid":false,"given":"Winson","family":"Cai","sequence":"additional","affiliation":[{"name":"1Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzhi","family":"Luo","sequence":"additional","affiliation":[{"name":"1Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aspen","family":"Pierson","sequence":"additional","affiliation":[{"name":"1Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Daniyan","sequence":"additional","affiliation":[{"name":"1Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Yoo","sequence":"additional","affiliation":[{"name":"1Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5573-1677","authenticated-orcid":false,"given":"Sumiko","family":"Takao","sequence":"additional","affiliation":[{"name":"1Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1165-6991","authenticated-orcid":false,"given":"Michael","family":"Kharas","sequence":"additional","affiliation":[{"name":"1Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"3Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Kentsis","sequence":"additional","affiliation":[{"name":"1Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"3Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Liu","sequence":"additional","affiliation":[{"name":"2Eureka Therapeutics Inc, Emeryville, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Scheinberg","sequence":"additional","affiliation":[{"name":"1Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"3Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"177","key":"2024020816243247200_bib1","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"issue":"4","key":"2024020816243247200_bib2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"2024020816243247200_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"issue":"2","key":"2024020816243247200_bib4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1053\/j.seminhematol.2018.08.008","article-title":"Will CAR T cell therapy have a role in AML? Promises and pitfalls","volume":"56","author":"Cummins","year":"2019","journal-title":"Semin Hematol"},{"issue":"1","key":"2024020816243247200_bib5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1186\/s13287-021-02420-8","article-title":"Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"2024020816243247200_bib6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3389\/fimmu.2020.00257","article-title":"TCR-like CAR-T cells targeting MHC-bound minor histocompatibility antigens","volume":"11","author":"Akatsuka","year":"2020","journal-title":"Front Immunol"},{"issue":"176","key":"2024020816243247200_bib7","doi-asserted-by":"crossref","first-page":"176ra33","DOI":"10.1126\/scitranslmed.3005661","article-title":"Targeting the intracellular WT1 oncogene product with a therapeutic human antibody","volume":"5","author":"Dao","year":"2013","journal-title":"Sci Transl Med"},{"issue":"10","key":"2024020816243247200_bib8","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/nbt.3349","article-title":"Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1","volume":"33","author":"Dao","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"5","key":"2024020816243247200_bib9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/jjco\/hyp194","article-title":"WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy","volume":"40","author":"Sugiyama","year":"2010","journal-title":"Jpn J Clin Oncol"},{"issue":"17","key":"2024020816243247200_bib10","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2024020816243247200_bib11","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3109\/14653249.2012.693744","article-title":"Dendritic cell vaccination in acute myeloid leukemia","volume":"14","author":"Anguille","year":"2012","journal-title":"Cytotherapy"},{"issue":"3","key":"2024020816243247200_bib12","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/bloodadvances.2017014175","article-title":"Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia","volume":"2","author":"Maslak","year":"2018","journal-title":"Blood Adv"},{"issue":"7","key":"2024020816243247200_bib13","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","article-title":"T\u00a0cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat Med"},{"issue":"15 pt 1","key":"2024020816243247200_bib14","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1158\/1078-0432.CCR-07-0708","article-title":"Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells","volume":"13","author":"May","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"174","key":"2024020816243247200_bib15","doi-asserted-by":"crossref","first-page":"174ra27","DOI":"10.1126\/scitranslmed.3004916","article-title":"Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients","volume":"5","author":"Chapuis","year":"2013","journal-title":"Sci Transl Med"},{"issue":"25","key":"2024020816243247200_bib16","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.2020010477","article-title":"Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody","volume":"138","author":"Augsberger","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2024020816243247200_bib17","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/leu.2016.373","article-title":"Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms tumor 1 antigen","volume":"31","author":"Rafiq","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"2024020816243247200_bib18","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jmb.2015.12.002","article-title":"Structure of a TCR-mimic antibody with target predicts pharmacogenetics","volume":"428","author":"Ataie","year":"2016","journal-title":"J\u00a0Mol Biol"},{"issue":"5","key":"2024020816243247200_bib19","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1172\/JCI130562","article-title":"Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA","volume":"130","author":"Holland","year":"2020","journal-title":"J\u00a0Clin Invest"},{"key":"2024020816243247200_bib20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41421-018-0066-6","article-title":"A\u00a0novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma\/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release","volume":"4","author":"Xu","year":"2018","journal-title":"Cell Discov"},{"issue":"7","key":"2024020816243247200_bib21","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1007\/s00432-022-04132-9","article-title":"A\u00a0novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed\/refractory B-cell lymphoma","volume":"149","author":"He","year":"2023","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"7","key":"2024020816243247200_bib23","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1182\/blood.V95.7.2198","article-title":"Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1","volume":"95","author":"Gao","year":"2000","journal-title":"Blood"},{"issue":"8","key":"2024020816243247200_bib22","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1182\/blood.V83.8.2103.2103","article-title":"Phenotype analysis of hematopoietic CD34+ cell populations derived from human umbilical cord blood using flow cytometry and cDNA-polymerase chain reaction","volume":"83","author":"Thoma","year":"1994","journal-title":"Blood"},{"issue":"4","key":"2024020816243247200_bib24","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","article-title":"Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors","volume":"38","author":"Leko","year":"2020","journal-title":"Cancer Cell"},{"issue":"11","key":"2024020816243247200_bib25","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"issue":"6","key":"2024020816243247200_bib26","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J"},{"issue":"4","key":"2024020816243247200_bib27","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0145-2126(84)90001-8","article-title":"A\u00a0monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells","volume":"8","author":"Griffin","year":"1984","journal-title":"Leuk Res"},{"issue":"5","key":"2024020816243247200_bib28","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/2326-6066.CIR-19-0745","article-title":"Identification of the targets of T-cell receptor therapeutic agents and cells by use of a high-throughput genetic platform","volume":"8","author":"Gejman","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"2024020816243247200_bib29","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nri3279","article-title":"Why must T cells be cross-reactive?","volume":"12","author":"Sewell","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"2024020816243247200_bib30","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/14712598.2016.1176138","article-title":"Opportunities and challenges for TCR mimic antibodies in cancer therapy","volume":"16","author":"Chang","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"2024020816243247200_bib31","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3389\/fimmu.2017.01467","article-title":"Membrane rafts in T cell activation: a spotlight on CD28 costimulation","volume":"8","author":"Zumerle","year":"2017","journal-title":"Front Immunol"},{"issue":"9","key":"2024020816243247200_bib32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0167-5699(98)01299-7","article-title":"A\u00a0very high level of crossreactivity is an essential feature of the T-cell receptor","volume":"19","author":"Mason","year":"1998","journal-title":"Immunol Today"},{"issue":"623","key":"2024020816243247200_bib33","doi-asserted-by":"crossref","first-page":"eabh1962","DOI":"10.1126\/scitranslmed.abh1962","article-title":"Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence","volume":"13","author":"Katsarou","year":"2021","journal-title":"Sci Transl Med"},{"issue":"1","key":"2024020816243247200_bib34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"4","key":"2024020816243247200_bib35","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1158\/2326-6066.CIR-21-0307","article-title":"A\u00a0costimulatory CAR improves TCR-based cancer immunotherapy","volume":"10","author":"Omer","year":"2022","journal-title":"Cancer Immunol Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/6\/507\/2211261\/blood_bld-2023-021054-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/6\/507\/2211261\/blood_bld-2023-021054-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T16:26:51Z","timestamp":1707409611000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/6\/507\/506498\/A-dual-receptor-T-cell-platform-with-Ab-TCR-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,2,8]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023021054","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]}}}